Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study

Xu, Zheng; Wang, Xin-Ming; Cao, Peng; Zhang, Chen; Feng, Chun-Mei; Zheng, Ling; Xu, De-Xiang; Fu, Lin; Zhao, Hui

doi:10.7150/ijms.67028



Theranostics

International Journal of Biological Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Med Sci 2022; 19(1):74-81. doi:10.7150/ijms.67028 This issue Cite

Research Paper

Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study

Zheng Xu^1*, Xin-Ming Wang^2*, Peng Cao¹, Chen Zhang¹, Chun-Mei Feng¹, Ling Zheng¹, De-Xiang Xu^3✉, Lin Fu^1✉, Hui Zhao^1✉

1. Respiratory and Critical Care Medicine, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, 230601, China.
2. Department of Pharmacy, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, 230022, China.
3. Department of Toxicology, Anhui Medical University, Hefei, Anhui Province, 230032, China.
* These authors contributed equally to this work.

Citation:

Xu Z, Wang XM, Cao P, Zhang C, Feng CM, Zheng L, Xu DX, Fu L, Zhao H. Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. Int J Med Sci 2022; 19(1):74-81. doi:10.7150/ijms.67028. https://www.medsci.org/v19p0074.htm

Other styles

Abstract

Background: The previous studies have revealed that IL-27 was involved in the pathophysiology of pulmonary inflammatory diseases. However, the role of IL-27 in community-acquired pneumonia (CAP) was unclear. The goal of this research was to explore the associations of serum IL-27 with the severity and prognosis among CAP patients through a prospective cohort study.

Methods: The whole of 239 healthy population and 239 CAP patients were enrolled. Fasting blood samples were collected. Inflammatory cytokines were detected using enzyme linked immunosorbent assay (ELISA). Demographic characteristics and clinical information were analyzed.

Results: Serum IL-27 on admission was significantly risen in CAP patients compared with control subjects. Besides, serum IL-27 was gradually increased in line with CAP severity scores. Correlative analysis suggested that serum IL-27 was associated with blood routine indices, renal function, liver function, myocardial function and inflammatory cytokines. Linear and logistic regression analyses revealed that serum IL-27 was positively correlated with CAP severity scores. Logistic regression analysis demonstrated that serum higher IL-27 on admission elevated the risks of vasoactive agent usage and longer hospital stay during hospitalization among CAP patients.

Conclusions: Serum IL-27 is markedly and positively associated with the severity and poor prognosis among CAP patients, indicating that IL-27 may involve in the pathophysiological process of CAP. Serum IL-27 may be used as a biomarker for diagnosis and prognosis in CAP patients.

Keywords: Community-acquired pneumonia, IL-27, Diagnosis, Prognosis, Biomarker.

Citation styles

APA

Xu, Z., Wang, X.M., Cao, P., Zhang, C., Feng, C.M., Zheng, L., Xu, D.X., Fu, L., Zhao, H. (2022). Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. International Journal of Medical Sciences, 19(1), 74-81. https://doi.org/10.7150/ijms.67028.

ACS

Xu, Z.; Wang, X.M.; Cao, P.; Zhang, C.; Feng, C.M.; Zheng, L.; Xu, D.X.; Fu, L.; Zhao, H. Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. Int. J. Med. Sci. 2022, 19 (1), 74-81. DOI: 10.7150/ijms.67028.

NLM

CSE

Xu Z, Wang XM, Cao P, Zhang C, Feng CM, Zheng L, Xu DX, Fu L, Zhao H. 2022. Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. Int J Med Sci. 19(1):74-81.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.